Parkinson’s & Movement Disorders

Movement disorders are entering a precision-medicine era, with genetically stratified trials in GBA1 (LTI-291/venglustat lessons, BIA 28-6156) and LRRK2 (BIIB122/DNL151) carriers redefining trial design. GCNN 2027 will cover the expanding device-aided therapy landscape — subcutaneous levodopa (ND0612, ABBV-951/foslevodopa-foscarbidopa), adaptive closed-loop DBS, and MRI-guided focused ultrasound subthalamotomy and pallidotomy. The track also addresses alpha-synuclein seed amplification assays as a biological diagnostic, prasinezumab and other anti-aggregation programs, and the emerging GLP-1 signal in Parkinson’s (exenatide LixiPark readout).